Update in transplantation 2005

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 6, 2006, Pages 593-598

  Estenne, Marc ^a   Kotloff, Robert M ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; AZITHROMYCIN; COMPLEMENT INHIBITOR; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; PREDNISONE; RIBAVIRIN; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE;

ALLOGRAFT; AREA UNDER THE CURVE; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; DOSE RESPONSE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; ISCHEMIA; LUNG FIBROSIS; LUNG FUNCTION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN DONOR; ORGAN PRESERVATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; TISSUE PRESERVATION; TREATMENT OUTCOME;

EID: 33644835656     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.2601012     Document Type: Review

References (60)

1. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: Twenty-Second Official Adult Lung and Heart-Lung Transplant Report - 2005. J Heart Lung Transplant 2005;24:956-967.
2. Luckraz H, White P, Sharples LD, Hopkins P, Wallwork J. Short- and long-term outcomes of using pulmonary allograft donors with low Po2. J Heart Lung Transplant 2005;24:470-473.
3. Thabut G, Mal H, Cerrina J, Dartevelle P, Dromer C, Velly JF, Stern M, Loirat P, Bertocchi M, Mornex JF, et al. Influence of donor characteristics on outcome after lung transplantation: a multicenter study. J Heart Lung Transplant 2005;24:1347-1353.
4. Fischer S, Gohrbandt B, Struckmeier P, Niedermeyer J, Simon A, Hagl C, Kallenbach K, Haverich A, Struber M. Lung transplantation with lungs from donors fifty years of age and older. J Thorac Cardiovasc Surg 2005;129:919-925.
5. Hartwig MG, Patel V, Palmer SM, Cantu E, Appel JZ, Messier RH, Davis RD. Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 2005;80:320-325.
6. Gamez P, Cordoba M, Ussetti P, Carreno MC, Alfageme F, Madrigal L, Nunez JR, Calatayud J, Ramos M, Salas C, et al. Lung transplantation from out-of-hospital non-heart-beating lung donors. one-year experience and results. J Heart Lung Transplant 2005;24:1098-1102.
7. Roe DW, Fehrenbacher JW, Niemeier MR, Zieger M, Labarrere C, Wilkes DS. Lung preservation: pulmonary flush route affects bronchial mucosal temperature and expression of IFN-gamma and Gro in regional lymph nodes. Am J Transplant 2005;5:995-1001.
8. Sommer SP, Gohrbandt B, Fischer S, Hohlfeld JM, Warnecke G, Avsar M, Struber M. Glutathione improves the function of porcine pulmonary grafts stored for twenty-four hours in low-potassium dextran solution. J Thorac Cardiovasc Surg 2005;130:864-869.
9. Wittwer T, Franke UF, Ochs M, Sandhaus T, Schuette A, Richter S, Dreyer N, Knudsen L, Muller T, Schubert H, et al. Inhalative pretreatment of donor lungs using the aerosolized prostacyclin analog iloprost ameliorates reperfusion injury. J Heart Lung Transplant 2005;24:1673-1679.
10. Wittwer T, Franke UF, Fehrenbach A, Ochs M, Sandhaus T, Schuette A, Richter S, Dreyer N, Knudsen L, Muller T, et al. Donor pretreatment using the aerosolized prostacyclin analogue iloprost optimizes postischemic function of non-heart beating donor lungs. J Heart Lung Transplant 2005;24:371-378.
11. Christie JD, Sager JS, Kimmel SE, Ahya VN, Gaughan C, Blumenthal NP, Kotloff RM. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005;127:161-165.
12. Meyers BF, de la Morena M, Sweet SC, Trulock EP, Guthrie TJ, Mendeloff EN, Huddleston C, Cooper JD, Patterson GA. Primary graft dysfunction and other selected complications of lung transplantation: a single-center experience of 983 patients. J Thorac Cardiovasc Surg 2005;129:1421-1429.
13. Christie JD, Kotloff RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005;171:1312-1316.
14. Yamane M, Liu M, Kaneda H, Uhlig S, Waddell TK, Keshavjee S. Reperfusion-induced gene expression profiles in rat lung transplantation. Am J Transplant 2005;5:2160-2169.
15. Ishiyama T, Dharmarajan S, Hayama M, Moriya H, Grapperhaus K, Patterson GA. Inhibition of nuclear factor kappaB by IkappaB super-repressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg 2005;130:194-201.
16. Quadri SM, Segall L, de Perrot M, Han B, Edwards V, Jones N, Waddell TK, Liu M, Keshavjee S. Caspase inhibition improves ischemia-reperfusion injury after lung transplantation. Am J Transplant 2005;5:292-299.
17. Thabut G, Mal H, Cerrina J, Dartevelle P, Dromer C, Velly JF, Stern M, Loirat P, Leseche G, Bertocchi M, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005;171:786-791.
18. Pilcher DV, Scheinkestel CD, Snell GI, Davey-Quinn A, Bailey MJ, Williams TJ. High central venous pressure is associated with prolonged mechanical ventilation and increased mortality after lung transplantation. J Thorac Cardiovasc Surg 2005;129:912-918.
19. Oto T, Levvey BJ, Pilcher DV, Bailey MJ, Snell GI. Evaluation of the oxygenation ratio in the definition of early graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2005;130:180-186.
20. Keshavjee S, Davis RD, Zamora MR, de Perrot M, Patterson GA. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005;129:423-428.
21. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005;171:1053-1059.
22. Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel PR, Dhainaut JF, Dusser D. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005;171:158-164.
23. McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, Zaldonis D, Johnson B, Hattler BG, Starzl TE. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005;130:528-537.
24. Knoop C, Thiry P, Saint-Marcoux F, Rousseau A, Marquet P, Estenne M. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant 2005;5:1477-1482.
25. Ragette R, Kamler M, Weinreich G, Teschler H, Jakob H. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transplant 2005;24:1315-1319.
26. Akhlaghi F, Gonzalez L, Trull AK. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. J Heart Lung Transplant 2005;24:2120-2128.
27. Snell GI, Levvey BJ, Zheng L, Bailey M, Orsida B, Law L, Whitford HM, Kotsimbos TC, Williams TJ. Everolimus alters the bronchoalveolar lavage and endobronchial biopsy immunologic profile post-human lung transplantation. Am J Transplant 2005;5:1446-1451.
28. Rocha PN, Rocha AT, Palmer SM, Davis RD, Smith SR. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 2005;5:1469-1476.
29. Mughal MM, Gildea TR, Murthy S, Pettersson G, DeCamp M, Mehta AC. Short-term deployment of self-expanding metallic stents facilitates healing of bronchial dehiscence. Am J Respir Crit Care Med 2005;172:768-771.
30. D'Ovidio F, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, Hadjiliadis D, Chaparro C, Gutierrez C, Pierre A, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005;129:1144-1152.
31. Ward C, Forrest IA, Brownlee IA, Johnson GE, Murphy DM, Pearson JP, Dark JH, Corris PA. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. Thorax 2005;60:872-874.
32. Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Aloush A, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005;5:2022-2030.
33. Hopkins PM, Aboyoun CL, Chhajed PN, Malouf MA, Plit ML, Rainer SP, Glanville AR. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004;170:1022-1026.
34. Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, Johnson G, Ayers M, Siegal D, Humar A. Clinical impact of communityacquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005;5:2031-2036.
35. Glanville AR, Gencay M, Tamm M, Chhajed P, Plit M, Hopkins P, Aboyoun C, Roth M, Malouf M. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005;24:131-136.
36. Kotsimbos TC, Snell GI, Levvey B, Spelman DW, Fuller AJ, Wesselingh SL, Williams TJ, Ostergaard L. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2005;79:269-275.
37. Neurohr C, Huppmann P, Leuchte H, Schwaiblmair M, Bittmann I, Jaeger G, Hatz R, Frey L, Uberfuhr P, Reichart B, et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005;5:2982-2991.
38. Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, Malouf MA. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005;24:2114-2119.
39. Girnita AL, Duquesnoy R, Yousem SA, Iacono AT, Corcoran TE, Buzoianu M, Johnson B, Spichty KJ, Dauber JH, Burckart G, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005;5:131-138.
40. Maruyama T, Jaramillo A, Narayanan K, Higuchi T, Mohanakumar T. Induction of obliterative airway disease by anti-HLA class I antibodies. Am J Transplant 2005;5:2126-2134.
41. Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, Schwartz DA. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005;171:780-785.
42. Medoff BD, Seung E, Wain JC, Means TK, Campanella GS, Islam SA, Thomas SY, Ginns LC, Grabie N, Lichtman AH, et al. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med 2005;202:97-110.
43. Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE, Fisher AJ, Dark JH, Lordan JL, Kirby JA, et al. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 2005;60:865-871.
44. Taghavi S, Krenn K, Jaksch P, Klepetko W, Aharinejad S. Bronchoalveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans. Am J Transplant 2005;5:1548-1552.
45. Murakawa T, Kerklo MM, Zamora MR, Wei Y, Gill RG, Henson PM, Grover FL, Nicolls MR. Simultaneous LFA-1 and CD40 ligand antagonism prevents airway remodeling in orthotopic airway transplantation: implications for the role of respiratory epithelium as a modulator of fibrosis. J Immunol 2005;174:3869-3879.
46. Belperio JA, Keane MP, Burdick MD, Gomperts B, Xue YY, Hong K, Mestas J, Ardehali A, Mehrad B, Saggar R, et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 2005;115:1150-1162.
47. Krebs R, Tikkanen JM, Nykanen AI, Wood J, Jeltsch M, Yla-Herttuala S, Koskinen PK, Lemstrom KB. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Respir Crit Care Med 2005;171:1421-1429.
48. Langenbach SY, Zheng L, McWilliams T, Levvey B, Orsida B, Bailey M, Williams TJ, Snell GI. Airway vascular changes after lung transplant: potential contribution to the pathophysiology of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2005;24:1550-1556.
49. Douglas IS, Nicolls MR. Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis? J Clin Invest 2005;115:1133-1136.
50. Lama VN, Murray S, Mumford JA, Flaherty KR, Chang A, Toews GB, Peters-Golden M, Martinez FJ. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med 2005;172:379-383.
51. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, Lordan JL, Dark JH, Corris PA. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005;172:772-775.
52. Williams TJ, Verleden GM. Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am J Respir Crit Care Med 2005;172:657-659.
53. Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005;5:537-543.
54. Meyer DM, Edwards LB, Torres F, Jessen ME, Novick RJ. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 2005;79:950-957. [Discussion, 957-958.]
55. Whelan TP, Dunitz JM, Kelly RF, Edwards LB, Herrington CS, Hertz MI, Dahlberg PS. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005;24:1269-1274.
56. Fitton TP, Kosowski TR, Barreiro CJ, Chan V, Patel ND, Borja MC, Orens JB, Conte JV. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005;24:1254-1259.
57. Rutherford RM, Fisher AJ, Hilton C, Forty J, Hasan A, Gould FK, Dark JH, Corris PA. Functional status and quality of life in patients surviving 10 years after lung transplantation. Am J Transplant 2005;5:1099-1104.
58. Bowdish ME, Pessotto R, Barbers RG, Schenkel FA, Starnes VA, Barr ML. Long-term pulmonary function after living-donor lobar lung transplantation in adults. Ann Thorac Surg 2005;79:418-425.
59. Wilkes DS, Egan TM, Reynolds HY. Lung transplantation: opportunities for research and clinical advancement. Am J Respir Crit Care Med 2005;172:944-955.
60. Parimon T, Madtes DK, Au DH, Clark JG, Chien JW. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med 2005;172:384-390.